Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

75.38EUR
19 Dec 2014
Price Change (% chg)

€-0.79 (-1.04%)
Prev Close
€76.17
Open
€76.30
Day's High
€76.52
Day's Low
€74.06
Volume
5,880,805
Avg. Vol
4,079,743
52-wk High
€89.95
52-wk Low
€68.29

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.60
Market Cap (Mil.): €100,027.40
Shares Outstanding (Mil.): 1,326.97
Dividend: 2.80
Yield (%): 3.71

Financials

  SASY.PA Industry Sector
P/E (TTM): 24.43 37.83 38.47
EPS (TTM): 3.09 -- --
ROI: -- 18.99 18.25
ROE: -- 19.75 19.13
Search Stocks

TRLPC-Sanofi agrees 8 bln euro loan refinancing

LONDON, Dec 17 - French drugmaker Sanofi has completed an 8 billion euro refinancing of its two syndicated revolving credit facilities, the company said in an email on Wednesday.

17 Dec 2014

Sanofi buys two equine health products from Bayer

PARIS - Sanofi said on Wednesday that Merial, its animal health unit, had reached an agreement with Bayer HealthCare to buy two Bayer equine health products for an undisclosed amount.

17 Dec 2014

Bayer to sell equine assets to Sanofi unit

FRANKFURT - German drugmaker Bayer said on Wednesday it had entered into a definitive agreement to sell veterinary products to treat horses to Sanofi's animal health unit Merial.

17 Dec 2014

Bayer to sell equine assets to Sanofi unit

FRANKFURT, Dec 17 - German drugmaker Bayer said on Wednesday it had entered into a definitive agreement to sell veterinary products to treat horses to Sanofi's animal health unit Merial.

17 Dec 2014

Sanofi buys two equine health products from Bayer

PARIS, Dec 17 - Sanofi said on Wednesday that Merial, its animal health unit, had reached an agreement with Bayer HealthCare to buy two Bayer equine health products for an undisclosed amount.

17 Dec 2014

Antibiotic developer Cempra's CEO says not looking for a buyer

- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers.

12 Dec 2014

Ex-Wyeth head Poussot to join Roche board, rather than Sanofi

PARIS - Former Wyeth chief executive Bernard Poussot looks to be out of the running to take over as the next boss of French drugmaker Sanofi, as Swiss rival Roche said on Friday he was joining its board.

12 Dec 2014

Ex-Wyeth head Poussot to join Roche board, rather than Sanofi

PARIS, Dec 12 - Former Wyeth chief executive Bernard Poussot looks to be out of the running to take over as the next boss of French drugmaker Sanofi, as Swiss rival Roche said on Friday he was joining its board.

12 Dec 2014

Sanofi to continue diversification, eyes acquisitions: Handelsblatt

FRANKFURT - Sanofi's new CEO will continue its strategy of diversifying beyond new drug development, possibly through acquisitions, the French drugmaker's interim chief executive said.

10 Dec 2014

Sanofi to continue diversification, eyes acquisitions -Handelsblatt

FRANKFURT, Dec 10 - Sanofi's new CEO will continue its strategy of diversifying beyond new drug development, possibly through acquisitions, the French drugmaker's interim chief executive said.

10 Dec 2014

Earnings vs. Estimates

Search Stocks